Related Experiment Video
Updated: Aug 20, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Revascularization strategies in acute myocardial infarction: a meta-analysis
A Bouzamondo1, T Damy, G Montalescot
1Pharmacology Department, Pitié-Salpêtrière Hospital, Paris, France. anissa.bouzamondo@psl.ap-hop-paris.fr
Insights
Stent implantation significantly reduces complications after myocardial infarction when added to angioplasty. Glycoprotein IIb/IIIa (GpIIb/IIIa) antagonists further improve outcomes, but careful use is needed to minimize bleeding risks.
Area of Science:
- Cardiology
- Interventional Cardiology
- Evidence-Based Medicine
Background:
- Myocardial infarction (MI) management aims to reduce complications.
- Various revascularization strategies, including thrombolysis, angioplasty, stenting, and glycoprotein IIb/IIIa (GpIIb/IIIa) antagonists, have been investigated.
Purpose of the Study:
- To assess the best evidence-based medicine revascularization strategy for reducing complications post-MI.
- To evaluate the efficacy of recent interventions like stent implantation and GpIIb/IIIa antagonists.
Main Methods:
- Meta-analysis of randomized controlled trials.
- Compared primary angioplasty with and without stent implantation.
- Assessed the addition of GpIIb/IIIa antagonists to angioplasty, angioplasty with stent, and thrombolytics.
- Primary outcome: death, MI, or urgent revascularization at 1 month.
Main Results:
- Stent addition to primary angioplasty reduced the combined endpoint by 31% at 30 days.
- GpIIb/IIIa antagonists reduced the combined endpoint by 50% with primary angioplasty and 42% with angioplasty + stent.
- GpIIb/IIIa antagonists with thrombolytics reduced the endpoint by 17% but increased major bleeding by 69%.
Conclusions:
- Stent implantation offers significant therapeutic benefit when combined with primary angioplasty for acute MI.
- GpIIb/IIIa antagonists provide additional benefits, contingent on minimizing bleeding complications.
Objective:
Many treatments and procedures have been tested to reduce complications after myocardial infarction. Our objective was to assess in this clinical situation the best evidence-based medicine revascularization strategy including the most recently developed interventions such as thrombolysis, angioplasty, stent implantation and glycoprotein IIb/IIIa (GpIIb/IIIa) antagonists.
Material And Methods:
We performed the meta-analyses of randomized controlled trials by testing the addition of a stent to primary angioplasty, the addition of GpIIb/IIIa antagonists to primary angioplasty, the addition of GpIIb/IIa antagonists to primary angioplasty + stent and finally addition of GpIIb/IIIa antagonists to thrombolytics. The primary outcome was the combined endpoint of death or myocardial infarction or urgent revascularization at 1 month.
Results:
The combined endpoint was significantly reduced by 31% (95% CI: 11% - 47%) at 30 days when stent was added to primary angioplasty. GpIIb/IIIa blockers provided an additional benefit by reducing the combined criteria by 50% (95% CI: 27% - 66%) in patients who underwent primary angioplasty, and by 42% (95% CI: 16% - 60%) when associated with angioplasty and stent implantation. Administration of GpIIb/IIIa in addition to thrombolytics, aspirin and heparin was associated with a significant reduction in the combined criteria by 17% (95% CI: 10% - 23%) and a significant excess of major bleeding by 69% (95% CI: 38% - 109%). However, the risk/benefit ratio indicates that patients with this association should be treated with the corresponding doses used in these trials.
Conclusion:
In acute myocardial infarction, stent implantation provides therapeutic benefit when added to primary angioplasty. The addition of GpIIb/IIIa blockers appears to provide further benefit if bleeding complications are minimized.
